Farshad Guirakhoo | CSO
Expression \bio

Farshad Guirakhoo, CSO, Expression \bio

Dr. Guirakhoo has 30+years of broad translational research experience in the vaccine development field. Dr. Guirakhoo was named as no. 22 in The Most Influential People in Vaccines. He is the co-inventor of the ChimeriVax™-technology platform, the world’s first recombinant viral vector platform that was approved for any human vaccine. Dr. Guirakhoo has broad experience in the application of genetics, gene expression technologies and molecular virology for the construction and production of recombinant proteins, human antibodies and attenuated viral vectored vaccines for prevention and treatment of infectious diseases and cancers. He is the author of over 100 peer-reviewed publications and holds dozens of issued patents.
Dr. Guirakhoo holds a PhD in Virology from the Medical University of Vienna, Austria.


Day 3 — Thursday October 19 @ 12:30

Preclinical proof of concept for a novel VLP-based vaccine candidate for treatment of HER2+ breast cancers

last published: 21/Sep/23 16:05 GMT

back to speakers